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Abstract Peptides binding to HLA-A11 contain a hydrophobic
or a small polar amino acid at position 2 and a lysine at the
carboxy terminus. Synthetic peptides carrying natural and
unnatural amino acids in position 2 were used to determine the
requirements for formation of stable HLA-A11/peptide com-
plexes. By kinetic analysis we demonstrate that a stereospecific
interaction between the side chain residue in position 2 and a
subsite of pocket B is required to obtain stable HLA/peptide
complexes. This specific interaction is mediated by a methyl
group or by an ethyl group bound to the asymmetric CL atom
with the correct configuration. Experiments performed with
different peptide sequences suggest that the presence of adequate
anchor residues may be sufficient to produce stable HLA/peptide
complexes.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Cytotoxic T lymphocytes (CTL) play an important role in
the control of viral, bacterial and parasitic infections, and can
recognize and destroy tumor cells [1]. The molecular targets of
their attack are peptide fragments selected for presentation by
major histocompatibility complex (MHC) class I molecules
[2]. MHC class I molecules are polymorphic glycoproteins
able to bind short peptides, 8^10 amino acids long, produced
by the intracellular degradation of proteins, and display them
on the cell surface for surveillance by CTL. Vaccination with
synthetic peptides, corresponding to immunogenic epitopes,
or with peptide-pulsed cells was shown to induce speci¢c
CTLs against immunogenic viral or tumor-derived epitopes
in vivo [3^6].
Molecular details of MHC/peptide association demon-
strated that the peptide binding site is localized in a groove
formed by the two K-helixes lying across an eight-stranded L-
pleated sheet [7,8]. The groove accommodates peptides in an
extended conformation, allowing the interaction of the amino
acid side chains with six de¢ned pockets, designated A to F,
that vary in shape, depth, and chemical composition and are
characteristic for each MHC allele. Peptides bound to a given
class I molecule show common amino acids at particular po-
sitions in the sequence, described as anchor residues, which
make speci¢c contacts with the groove of class I molecules [9].
These anchor residues, usually positions 2 and 9 of the peptide
sequence, interact with pockets B and F respectively, and are
necessary for binding.
We have previously shown that peptides binding to the
human allele histocompatibility leukocyte antigen (HLA)-
A11 contain a hydrophobic or a small polar amino acid at
position 2 (p2) and a lysine at the carboxy terminus [10].
Furthermore, we have characterized the molecular require-
ments for p2 occupancy of HLA-A11 binding peptides by
the use of a new approach based on the evaluation of
HLA-peptide stability. This parameter, in contrast with pep-
tide binding experiments performed with isolated HLA mole-
cules, is relevant for determining the functionality of HLA/
peptide complexes. By these studies we demonstrated that all
peptides capable of forming stable complexes with HLA-A11
molecules carry in position 2 an amino acid with a branched
side chain and methyl groups on the CL atom [11]. This res-
idue may be necessary for binding an hydrophobic site of the
B pocket.
In order to evaluate in detail the role of the methyl group in
the binding between pocket B of HLA-A11 and peptide an-
chor position 2 we performed a series of studies using syn-
thetic peptides, carrying natural and unnatural amino acids in
position 2.
2. Materials and methods
2.1. Cell lines
The W174/T2 cell line (T2) was obtained by fusion of the peptide
transporter mutantW174 LCL with the T cell line CEM [12]. An HLA-
A11 positive subline (T2/A11) was obtained by transfection of a ge-
nomic HindIII fragment containing the HLA-A11 coding sequence
[13]. Cell lines were maintained in RPMI 1640 (Gibco) supplemented
with 2 mM glutamine, antibiotics, 10% heat inactivated fetal calf
serum and 200 Wg/ml hygromycin B (Sigma).
2.2. Peptide synthesis
Peptides were synthesized by solid-phase method using a continu-
ous £ow instrument with on-line UV monitoring (Milligen, Biosearch
9050). The stepwise syntheses were carried out by Fmoc-chemistry; no
special e¡orts were made to optimize the coupling steps. The Fmoc-
MBHA resin was swollen in DMF and packed in the reaction column.
Fmoc-amino acids were coupled in a 4-fold excess using diisopropyl-
carbodiimide in the presence of the HOBt. The Fmoc group was
cleaved with 20% piperidine-DMF solution. Protected peptides were
cleaved from the resin by treatment with modi¢ed reagent B (88%
TFA, 5% H2O, 7% Et3SiH) and the resulting products were collected
by centrifugation and puri¢ed by preparative HPLC (puri¢cation
yield 79^90%).
A di¡erent method was developed for the IVT analogue containing
a residue of homoserine in position 2. The di⁄culty in incorporating
homoserine into synthetic peptides stems from the well-known ten-
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dency of Q-hydroxyamino acids and their derivatives to form a Q-lac-
tone. The key to this synthesis was the introduction, during the solid-
phase procedure, of the dipeptide Fmoc-Hse-Thr-OH prepared by
solution method to Boc-Asp-Thr-OtBu, and the subsequent conver-
sion by chemoselective reduction of the side chain carboxylic function
[14].
The amino acid sequences of the peptides in single letter code were:
IVTDFSVIK (IVT), derived from EBV nuclear antigen-4 aa 416^424
[15]; AIFQSSMTK (AIF), derived from the HIV pol antigen aa 325^
333 [10]; YVNVNMGLK (YVN), derived from the HBV nucleocap-
sid antigen aa 88^96 [16]; and ELNEALELK (ELN), derived from
wild-type p53 aa 343^351 [10]. The IVT analogues carrying amino
acid substitutions in position 2 are referred to as [x]2IVT.
2.3. Peptide analytical determinations
Homogeneity of the puri¢ed products was assessed by analytical
HPLC. Structure veri¢cation was achieved by elemental and amino
acid analyses and MALDI-TOF mass spectrometry. The physico-
chemical data of synthetic peptides are reported in Table 1. Melting
points were determined by a Ko£er apparatus and are uncorrected.
Optical rotations were determined using a Perkin Elmer 141 polar-
imeter with a 10 cm Water jacketed cell. Matrix-assisted laser desorp-
tion ionization time-of-£ight (MALDI-TOF) was obtained using the
HPG2025A mass spectra. HPLC analysis was performed on a Bruker
liquid chromatograph LC21-C instrument, using a Vydac C 18 218 TP
5415 column (175U4.5 mm, 5 mm particle size) equipped with a
Bruker LC 313 UV variable wavelength detector; recording and quan-
ti¢cation were accomplished with a chromatographic data processor
(Epson computer FX80X7). Analytical determinations were carried
out by a gradient made up of two solvents: A, 10% (v/v) acetonitrile
in water and B, 60% (v:v) acetonitrile in water, both containing 0.1%
TFA. The gradient program used was linear gradient from 0 to 100%
B in 25 min at a £ow of 1 ml/min. All analogues showed purity
greater than 99% following analytical HPLC monitored at 220 nm.
Preparative reversed-phase HPLC was carried out with a Water Delta
Prep 3000 using a Delta Pack C 18-300 A (30 mmU30 cm, 15 mm,
spherical). The gradient used was identical to that of analytical deter-
minations. Chromatography was performed at a £ow rate of 30 ml/
min. Amino acid analyses were carried out using PITC methodology
as the amino acid derivatization reagent (Pico-Tag, Waters-Millipore,
Waltham, MA, USA). Lyophilized samples of peptides (50^100 pmol)
were placed in heat-treated borosilicate tubes (50U4 mm), sealed and
hydrolysed using 200 ml 6 N HCl containing 1% phenol in the Pico-
Tag work station for 1 h at 150‡C. A Hypersil ODS column (250U4.6
mm, 5 mm particle size) was employed to separate the PITC-amino
acid derivatives.
2.4. Detection of peptide binding to HLA-A11 class I molecules by
immuno£uorescence
Aliquots of 1U106 T2/A11 cells were cultured overnight in 1 ml
serum-free medium containing 1034 M of the indicated peptides. Cells
were then extensively washed and resuspended in PBS. Surface ex-
pression of HLA class I molecules was detected by indirect immuno-
£uorescence using the mouse mAb, W6-32, which is speci¢c for HLA-
A, -B, -C molecules, AUF5.13, which is speci¢c for HLA-A3 and
-A11 class I antigens, and BB7.2, which is speci¢c for HLA-A2 mol-
ecules. Data are expressed as mean logarithm £uorescence intensity
measured with a FACS analyser [10].
2.5. Detection of HLA-A11/peptide complex stability
Aliquots of 5U106 T2/A11 cells were cultured overnight in 5 ml
serum-free medium containing 1034 M of the indicated peptides. Cells
were then extensively washed, treated with mitomycin C (Sigma) to
avoid cell proliferation, divided in aliquots in serum-free medium and
maintained at 37‡C for kinetic experiments. Surface expression of
HLA class I molecules was detected by indirect immuno£uorescence
using the mouse mAb W6-32, which is speci¢c for HLA-A, -B, -C
molecules. Data are expressed as mean logarithm £uorescence inten-
sity measured with a FACS analyser [10].
3. Results
3.1. Association of IVT analogues with HLA-A11 molecules
A previously identi¢ed HLA-A11 binding peptide was chos-
en as a model for these studies. This peptide, IVTDFSVIK
(IVT), aa 416^424, derived from the Epstein-Barr virus nu-
clear antigen 4 (EBNA4), was previously shown to e⁄ciently
associate with HLA-A11 molecules since it induced high and
stable levels of surface HLA-A11 expression in the HLA-A11
transfected T2 mutant cell line (T2/A11) [10,11].
We synthesized the IVT peptide and a series of synthetic
analogues (Table 1 and Fig. 1), di¡ering from the original
sequence by single amino acid substitution in position 2
(p2). The p2 amino acids were chosen to evaluate the phys-
ico-chemical and steric role of the methyl group on the CL
atom of the side chain in interaction with A11 molecules.
Thr and Ile amino acids have previously been shown to
represent p2 residues of peptide sequences that stably associ-
ate with HLA-A11; these were used as positive controls in all
assays. Both residues present the methyl group on CL [11].
AlloThr and alloIle carry a CL with an opposite con¢guration
with respect to Thr and Ile and consequently the methyl
group on CL has a di¡erent spatial disposition. In allo-amino
acids the hydroxyl group of alloThr and the ethyl group of
alloIle occupy the position of the methyl group in the corre-
spondent natural residues. Abu and Hse present hydrophobic
and hydrophilic side chains with steric hindrance similar to
Thr; Leu presents a hydrophobic side chain with steric hin-
drance similar to Ile. Abu, Hse and Leu do not present the
methyl group on CL nor C asymmetry in the side chain.
The peptide CLGGLLTMV (CLG), derived from the EBV
antigen LMP2 [17], associates with HLA-A2 molecules and
has been used as control in all assays.
All peptides were tested for their ability to associate with
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Table 1
Physicochemical properties of synthetic peptides
Name Sequence M.p. (‡C) K20D a tRb MS [M+H]
Calcd. Found
IVT H-Ile-Val-Thr-Asp-Phe-Ser-Val-Ile-Lys-OH 178^180 319.5 13.8 1022.8 1022.8
[Thr]2IVT H-Ile-Thr-Thr-Asp-Phe-Ser-Val-Ile-Lys-OH 194^197 329.4 12.3 1024.7 1024.7
[alloThr]2IVT H-Ile-alloThr-Thr-Asp-Phe-Ser-Val-Ile-Lys-OH 183^185 321.4 12.6 1024.7 1024.7
[Hse]2IVT H-Ile-Hse-Thr-Asp-Phe-Ser-Val-Ile-Lys-OH 199^202 323,8 13.3 1024.7 1024.7
[Abu]2IVT H-Ile-Abu-Thr-Asp-Phe-Ser-Val-Ile-Lys-OH 205^208 320.5 13.7 1008.8 1008.8
[Ile]2IVT H-Ile-Ile-Thr-Asp-Phe-Ser-Val-Ile-Lys-OH 227^229 315.2 14.1 1036.8 1036.8
[alloIle]2IVT H-Ile-alloIle-Thr-Asp-Phe-Ser-Val-Ile-Lys-OH 215^219 325.2 14.5 1036.8 1036.8
[Leu]2IVT H-Ile-Leu-Thr-Asp-Phe-Ser-Val-Ile-Lys-OH 184^186 317.3 14.8 1036.8 1036.8
ELN H-Glu-Leu-Asn-Glu-Ala-Leu-Glu-Leu-Lys-OH 211^214 39.8 8.9 1058.2 1058.2
AIF H-Ala-Ile-Phe-Gln-Ser-Ser-Met-Thr-Lys-OH 209^211 340.7 7.3 1012.1 1012.1
YVN H-Tyr-Val-Asn-Val-Asn-Met-Gly-Leu-Lys-OH 198^201 322.9 9.4 1037.2 1037.2
ac 1.0, methanol; btR : retention time in HPLC, see Section 2 for conditions.
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HLA-A11 molecules expressed at the surface of intact cells.
HLA-A11/peptide association was assessed by the induction
of surface HLA-A11 expression in the T2/A11 mutant cell line
[18]. T2/A11 cells were treated at 26‡C for 18 h in serum-free
medium to induce high levels of empty molecules at the cell
surface [19] and then exposed to 1034 M of peptides at 37‡ for
1 h. The cells were extensively washed to remove the unbound
peptides, treated with brefeldin A to block the egress of new
class I molecules, and the surface expression of HLA class I
complexes was evaluated by immuno£uorescence using the
following monoclonal antibodies: W6-32, speci¢c for HLA-
A, -B, -C class I molecules, AUF5.13, speci¢c for HLA-A11,
and BB7.2 speci¢c for HLA-A2.
Results obtained with the W6-32 and AUF5.13 antibodies
showed that the IVT analogues with the amino acids Ile,
alloIle, Abu, Hse and Leu in p2 speci¢cally associate with
HLA-A11 molecules showing an e⁄ciency comparable to
that obtained using the original IVT peptide. An apparent
discrepancy between the two detecting antibodies was ob-
served with peptides carrying Thr and alloThr in p2. The
HLA-A11/peptide complexes were e⁄ciently detected by
W6-32 mAb, but not by AUF5.13 mAb. We have previously
shown that this phenomenon is due to the restricted speci¢city
of AUF5.13 mAb for a particular subset of HLA-A11/peptide
complexes [11,20]. None of the peptides used was cross-reac-
tive with HLA-A2 molecules, in that they did not a¡ect HLA-
A2 expression on T2/A11 (Table 2).
3.2. Stability of HLA/peptide complexes
All the IVT analogues were compared for their capacity to
form stable HLA-A11/peptide complexes at the cell surface of
T2/A11 cells. After peptide pulsing the cells were extensively
washed, mitomycin C treated to avoid proliferation, and
tested for HLA-A11 expression in kinetic experiments.
HLA-A11 expression was assessed by the use of W6-32
mAb because of its ability to recognize all class I molecules
independently of the associated peptide.
Similar levels of HLA-A11 surface expression were ob-
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Fig. 2. Kinetic expression of HLA-A11/IVT analogue complexes. T2/A11 cells were preincubated overnight at 37‡C with 1034 M of the indi-
cated peptides, washed, divided in 3 aliquots in serum-free medium and maintained at 37‡C for kinetic experiments. Surface expression of HLA
class I molecules was detected by indirect immuno£uorescence using the mouse mAb W6-32. Data are expressed as mean £uorescence intensity
measured with a FACS analyser. Mean þ S.D. of 4 di¡erent experiments.
Fig. 1. Schematic representation of stereochemistry of the amino acids at position 2 in IVT peptide analogues.
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served at time 0 on T2/A11 cells pulsed with the di¡erent
peptides. T2/A11 cells that were pulsed with the IVT peptide
expressed stable levels of HLA-A11/IVT complexes at the cell
surface up to 12 h, and the complexes were still detectable
over a 48 h period. The [Thr]2IVT, [Ile]2IVT and [alloIle]2IVT
analogues showed similar kinetics. In contrast, a net decrease
of HLA-A11 expression was observed after just 6 h on T2/
A11 cells pulsed with the [alloThr]2IVT, [Hse]2IVT and [Leu]-
2IVT analogues, and HLA-A11 expression reached basal lev-
els at 24 h. A similar kinetic behavior was observed with cells
treated with the [Abu]2IVT peptide with the exception that
detectable HLA-A11 molecules were present at 24 h but com-
pletely disappeared at 48 h (Fig. 2).
3.3. E¡ect of p2 amino acids in other peptide sequences on
HLA-A11 expression
In this set of experiments we evaluated the role of the ami-
no acids in position 2 in unrelated nonamer peptide sequen-
ces. HLA-A11 binding peptides of di¡erent origin, derived
from viral and cellular antigens, were tested for their ability
to produce stable complexes with HLA-A11 molecules. T2/
A11 cells were treated with 1034 M of YVN, AIF and ELN
peptides and the HLA-A11 expression was tested in kinetic
experiments.
YVN and AIF peptides, carrying the amino acids Val and
Ile at the second position, formed stable complexes with
HLA-A11 molecules. In contrast, the ELN peptide, carrying
the amino acid Leu, did not stably associate with the A11
antigen (Fig. 3).
4. Discussion
The pool-sequencing analysis of naturally processed pep-
tides presented by a particular HLA class I allele revealed
that the majority of these peptides are 9 amino acids long
and have speci¢c residues, termed anchors, that allow binding
to class I molecules [9]. The molecular interactions between
peptides and HLA molecules seem particularly important in
determining the type of immunological response; indeed, it
has been demonstrated that peptides which stably bind to
HLA molecules represent immunodominant targets of CTL
activity [21,22].
We have previously shown that the HLA-A11 binding pep-
tides present hydrophobic or small polar residues in position 2
and a lysine in position 9 [10]. In contrast to the strict require-
ment for lysine in position 9, a large number of amino acids
seem to be accepted in the second position. However, only
residues with a branched side chain and methyl groups on
the CL atom were able to form stable complexes with HLA-
A11 molecules [11]. The p2 amino acid interacts with pocket B
of the peptide binding groove, constituted by hydrophobic
amino acids at the bottom and polar and charged amino acids
at the top [23].
In the present report, a detailed study on the interaction
between the methyl group in the anchor position 2 (p2) of the
peptide ligand and HLA-A11 class I molecules was performed
by analysing peptide binding and the stability of HLA/peptide
complexes. We have shown that all IVT p2 analogues are able
to associate with HLA-A11, suggesting that pocket B is a
complex region that permits multiple interactions with lig-
ands. Indeed, it accommodates both linear and branched res-
idues carrying aliphatic and/or hydroxyl groups.
IVT p2 analogues exhibited a di¡erent behavior when their
ability to produce stable HLA-A11/peptide complexes was
tested. Kinetic analysis, aimed at assessing the stability of
complexes for up to 48 h, revealed peptides with the capability
to produce stable HLA/peptide complexes.
The [alloThr]2IVT, [Abu]2IVT, [Hse]2IVT and [Leu]2IVT
analogues dissociated from HLA-A11 molecules within 24 h
of culture at 37‡C; on the contrary, the [Thr]2IVT, [Ile]2IVT
and [alloIle]2IVT analogues yielded stable complexes, with
kinetics comparable to that of IVT.
The di¡erent behavior of IVT p2 analogues suggests that at
least two interactions between the side chain residue in p2 and
pocket B are required to obtain stable HLA/peptide com-
plexes. One of these interactions has to be mediated by a
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Fig. 3. Kinetic expression of HLA-A11/peptide complexes. T2/A11
cells were preincubated overnight at 37‡C with 1034 M of the indi-
cated peptides, washed, divided in 3 aliquots in serum-free medium
and maintained at 37‡C for kinetic experiments. Surface expression
of HLA class I molecules was detected by indirect immuno£uores-
cence using the mouse mAb W6-32. Data are expressed as mean £u-
orescence intensity measured with a FACS analyser. Mean þ S.D. of
3 di¡erent experiments.
Table 2
Induction of surface HLA class I expression by peptides
Peptide HLA class I expressiona
W6-32 AUF5.13 BB7.2
None 78 þ 12 8 þ 6 18 þ 9
IVT 345 þ 22 65 þ 12 20 þ 4
[Thr]2IVT 348 þ 28 14 þ 4 21 þ 5
[alloThr]2IVT 289 þ 30 14 þ 4 24 þ 6
[Hse]2IVT 300 þ 19 66 þ 10 19 þ 5
[Abu]2IVT 300 þ 24 60 þ 11 19 þ 6
[Ile]2IVT 379 þ 10 64 þ 16 18 þ 6
[alloIle]2IVT 365 þ 18 68 þ 12 18 þ 8
[Leu]2IVT 335 þ 20 63 þ 10 18 þ 5
CLG 280 þ 6 7 þ 8 98 þ 14
aMean £uorescence intensity. T2/A11 cells were incubated overnight
in medium alone or medium containing 100 WM of the indicated
peptides. HLA class I expression was measured by FACS analysis
after indirect immuno£uorescence staining with the W6-32 mAb,
which is speci¢c for HLA-A, -B, -C molecules, AUF 5.13 mAb, which
is speci¢c for HLA-A11 class I antigens, and BB7.2 mAb, which is
speci¢c for HLA-A2 molecules. Mean þ S.D. of 4 experiments.
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methyl group (Val, Thr, Ile) or by an ethyl group (alloIle)
bound to the asymmetric CL atom with the correct con¢gu-
ration. The Abu residue presents the methyl group on CL
atom but, independently of the -CH3 spatial disposition, is
able to mediate only one interaction with pocket B, whereas
two binding sites are required for stability.
From these data it appears that pocket B of HLA-A11
contains a region able to bind polar or non-polar groups,
and a speci¢c hydrophobic subsite which mediates interac-
tions exclusively with groups bound to the asymmetric CL
atom of the p2 residue. These interactions may stabilize the
HLA/peptide complex either directly or by inducing confor-
mational changes in the bound peptide allowing a more favor-
able orientation of the N- and C-peptide terminal and/or non-
anchor residue groups.
Experiments performed with peptide sequences other than
IVT (ELN, AIF, YVN) con¢rmed the key role of the alkyl
group on the CL atom of the p2 residue, in that AIF and
YVN peptides yielded stable complexes while ELN did not.
This indicates that the presence of adequate anchor residues is
necessary and may be su⁄cient to produce stable HLA/pep-
tide complexes.
In conclusion, we have shown that the interactions between
the anchor positions of peptides and HLA class I molecules
are highly speci¢c, and determine the e⁄ciency of presenta-
tion of immunogenic peptides.
The precise identi¢cation of the role of anchor residues in
binding to HLA class I molecules could be particularly useful
for the design of highly immunogenic synthetic peptides de-
rived from subdominant epitopes which do not carry proper
anchor amino acids. Peptides with increased a⁄nity may be
able to enhance stimulation of speci¢c CTL responses directed
against natural epitopes. Such high a⁄nity peptides may be
useful for CTL-based vaccines and immunotherapy.
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